LGND
NASDAQ
US
Ligand Pharmaceuticals Incorporated - Common Stock
$199,59
▼ $-0,03
(-0,02%)
Vol. 222K
11
Punteggio di Qualità
ok
Analisi approfondita
1/5
fail
Ricavi ✗
Utile netto ✓
>IPO ✗
Cap. mercato
$3.7B
P/E
76,6
ROE
5,7%
Margine
19,3%
D/E
46,89
Beta
1,52
52W
$94–$212
Consenso Wall Street
15 analisti · Apr 20266
Acquisto forte
8
Compra
1
Mantieni
0
Vendi
0
Vendita forte
93,3%
Rating Compra
Grafico dei Prezzi
Titoli simili
AXSM
Axsome Therapeutics Inc
$9.2B
BLTE
Belite Bio Inc
$5.6B
TERN
Terns Pharmaceuticals Inc
$4.3B
CORT
Corcept Therapeutics Inc
P/E 34,5
$3.7B
AMRX
Amneal Pharmaceuticals Inc
P/E 671,4
$4.0B
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
INDV
Indivior Pharmaceuticals, Inc
P/E 35,8
$4.5B
GPCR
Structure Therapeutics Inc
$4.2B
EWTX
Edgewise Therapeutics Inc
$2.6B
LQDA
Liquidia Corp
$3.0B
Utili
Tasso di battuta: 100,0%
Prossimo report
Mag 06, 2026
Stima EPS: $2,02
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $2,02 | — | — |
| Dic 2025 | $1,59 | $2,02 | +$0,43 |
| Set 2025 | $1,96 | $3,09 | +$1,13 |
| Giu 2025 | $1,45 | $1,60 | +$0,15 |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -9.2% | -9.2% | -9.2% | -9.2% | 5.7% | 5.7% |
| P/E (TTM) | — | — | — | — | 79.04 | 76.60 |
| Net Margin | 10.2% | -40.4% | -40.4% | -40.4% | 19.3% | 19.3% |
| Gross Margin | 93.9% | 93.0% | 93.0% | 93.0% | 94.3% | 94.3% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 46.89 | 46.89 |
| Current Ratio | 5.45 | 5.45 | 5.45 | 5.45 | 24.69 | 24.69 |
Rapporti chiave
ROA (TTM)
4,6%
P/S (TTM)
14,81
P/B
2,4
EPS (TTM)
$2,08
CF/Share
$4,86
Crescita ricavi 3A
-15,5%
52W High
$212,49
52W Low
$93,58
$93,58
Intervallo 52 settimane
$212,49
Як LGND виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Mid-cap Pharmaceuticals ($2B+) · 25 компаній
Оцінка LGND vs аналоги Pharmaceuticals
P/E
76,6
▲
150%
sopra
peer
(30,7)
vs Peer
vs Settore
Sottovalutato
P/S
14,8
▲
120%
sopra
peer
(6,7)
vs Peer
vs Settore
Più costoso
P/B
2,4
▼
53%
sotto
peer
(5,2)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(3,1%)
vs Peer
vs Settore
Rendimento basso
Прибутковість LGND vs аналоги Pharmaceuticals
ROE
5,7%
▲
122%
sopra
peer
(-26,1%)
vs Peer
vs Settore
Top livello
Net margin
19,3%
▲
1434%
sopra
peer
(-1,5%)
vs Peer
vs Settore
Sotto media
Валова маржа
94,3%
▲
6%
sopra
peer
(88,9%)
vs Peer
vs Settore
In linea
ROA
4,6%
▲
148%
sopra
peer
(-9,5%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя LGND vs аналоги Pharmaceuticals
D/E ratio
46,9
▲
71%
sopra
peer
(27,4)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
24,7
▲
609%
sopra
peer
(3,5)
vs Peer
vs Settore
Liquidità forte
Beta
1,5
▲
157%
sopra
peer
(0,6)
vs Peer
vs Settore
Più volatile
Радар фундаменталів LGND
LGND
Mediana peer
Industria
LGND прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
LGND vs аналоги: ключові метрики
Ultime notizie
Nessuna notizia correlata ancora